High GADA titer increases the risk of insulin requirement in LADA patients: A 7-year follow-up (NIRAD study 7)

Simona Zampetti, Giuseppe Campagna, Claudio Tiberti, Marco Songini, Maria Luisa Arpi, Giuseppina De Simone, Efisio Cossu, Lorenzo Cocco, John Osborn, Emanuele Bosi, Francesco Giorgino, Marialuisa Spoletini, Raffaella Buzzetti

Research output: Contribution to journalArticle

Abstract

Objective: The aim of this study was to determine whether glutamic acid decarboxylase antibody (GADA) titer and other clinical parameters could define the risk of progression to insulin therapy in latent autoimmune diabetes in adults (LADA) patients during a 7-year follow-up. Methods: This study involved 220 LADA and 430 type 2 diabetes subjects followed up for 7 years from the time of GADA screening to evaluate their progression toward insulin therapy. Kaplan-Meier curves and multivariate logistic regression analysis were performed to identify the markers capable of influencing this progression. Results: During the follow-up, the drop out was 4% in both groups. A total of 119 (56.1%) out of 212 LADA patients required insulin during the 7 years of follow-up. The Kaplan-Meier plots showed that 74/104 (71.1%) of high GADA titer required insulin compared with 45/108 (41.6%) of low GADA titer and with 86/412 (20.9%) of type 2 diabetes ( P2 and IA-2IC and zinc transporter 8 (ZnT8) positivity were also shown as the markers of faster progression (PIC positivity and sulfonylurea treatment, in the first year from diagnosis, significantly increase the progression toward insulin requirement in LADA patients.

Original languageEnglish
Pages (from-to)697-704
Number of pages8
JournalEuropean Journal of Endocrinology
Volume171
Issue number6
DOIs
Publication statusPublished - Dec 1 2014

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Fingerprint Dive into the research topics of 'High GADA titer increases the risk of insulin requirement in LADA patients: A 7-year follow-up (NIRAD study 7)'. Together they form a unique fingerprint.

  • Cite this

    Zampetti, S., Campagna, G., Tiberti, C., Songini, M., Arpi, M. L., De Simone, G., Cossu, E., Cocco, L., Osborn, J., Bosi, E., Giorgino, F., Spoletini, M., & Buzzetti, R. (2014). High GADA titer increases the risk of insulin requirement in LADA patients: A 7-year follow-up (NIRAD study 7). European Journal of Endocrinology, 171(6), 697-704. https://doi.org/10.1530/EJE-14-0342